Research map: Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

Back to the article

Papers in this map

  1. FcRn: the neonatal Fc receptor comes of age · Derry C. Roopenian · 2007 · 2341 citations · Cited by this paper
  2. Comment on “Understanding Atomoxetine Exposure Variability in Children and Adolescents with ADHD through Population Pharmacokinetics” · 2026 · Related
  3. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma · David G. Maloney · 1997 · 1712 citations · Cited by this paper
  4. A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants with End‐Stage Kidney Disease on Hemodialysis · 2026 · Related
  5. The therapeutic monoclonal antibody market · Dawn M. Ecker · 2014 · 1311 citations · Cited by this paper
  6. A Phase 1 Oral Mass Balance and Combined Intravenous [ 14 C] Microtracer Study to Characterize the Absorption, Metabolism, Excretion, and Pharmacokinetics of Antitumor Drug E7386 in Humans · 2026 · Related
  7. Pharmacokinetics of Monoclonal Antibodies · Josiah T. Ryman · 2017 · 810 citations · Cited by this paper
  8. Population Pharmacokinetic Modeling of Intravenous Topiramate in Patients with Epilepsy or Migraine · 2026 · Related
  9. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. · DG Maloney · 1997 · 644 citations · Cited by this paper
  10. Volumetric Absorptive Microsampling During Spaceflight for Analysis of Acetaminophen Pharmacokinetics in Whole Blood · 2026 · Related
  11. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications · Kenneth G. C. Smith · 2010 · 549 citations · Cited by this paper
  12. Decoupling CAR‐T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi‐Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model · 2026 · Related
  13. Population Pharmacokinetics of Therapeutic Monoclonal Antibodies · Nathanael L. Dirks · 2010 · 498 citations · Cited by this paper
  14. Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine‐to‐Caffeine Metabolic Ratio: A Pharmacokinetic Study · 2026 · Related
  15. Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma · Jeffrey S. Weber · 2008 · 465 citations · Cited by this paper
  16. Pharmacokinetics, Safety, and Tolerability of Anti‐miR‐17 Oligonucleotide RGLS4326 in Healthy Adult Subjects · 2026 · Related
  17. Antibodies to watch in 2019 · Hélène Kaplon · 2018 · 447 citations · Cited by this paper
  18. Population Pharmacokinetics and Exposure‐Safety Analysis of Furosemide in Preterm Infants · 2026 · Related
  19. Antibodies to watch in 2020 · Hélène Kaplon · 2019 · 442 citations · Cited by this paper
  20. Population Pharmacokinetics of Oral Gecacitinib in Healthy Subjects and Patients with Autoimmune and Inflammatory Diseases · 2026 · Related
  21. Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer · David B. Agus · 2005 · 392 citations · Cited by this paper
  22. FDA Approval: Blinatumomab · Donna Przepiorka · 2015 · 375 citations · Cited by this paper
  23. Marketed therapeutic antibodies compendium · Janice M. Reichert · 2012 · 370 citations · Cited by this paper
  24. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial · Christopher Ryan Heery · 2017 · 304 citations · Cited by this paper
  25. Antibodies to watch in 2021 · Hélène Kaplon · 2021 · 297 citations · Cited by this paper
  26. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease · Maria Rosario · 2015 · 268 citations · Cited by this paper
  27. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus · Richard Alan Furie · 2008 · 265 citations · Cited by this paper
  28. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors · Gaurav Bajaj · 2016 · 264 citations · Cited by this paper
  29. A first-in-human phase 1 study of ACE910, a novel factor VIII–mimetic bispecific antibody, in healthy subjects · Naoki Uchida · 2015 · 261 citations · Cited by this paper
  30. Antibodies to watch in 2018 · Hélène Kaplon · 2018 · 248 citations · Cited by this paper
  31. Antibodies to watch in 2017 · Janice M. Reichert · 2016 · 246 citations · Cited by this paper
  32. Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study · Asit Parikh · 2011 · 212 citations · Cited by this paper
  33. A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease · Razelle Kurzrock · 2013 · 206 citations · Cited by this paper
  34. Antibodies to watch in 2016 · Janice M. Reichert · 2015 · 176 citations · Cited by this paper
  35. Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status · Paul Baverel · 2017 · 159 citations · Cited by this paper
  36. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial · Nizar Jacques Bahlis · 2023 · 159 citations · Cited by this paper
  37. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma · Mark Stroh · 2016 · 157 citations · Cited by this paper
  38. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study · Mark A Agius · 2017 · 151 citations · Cited by this paper
  39. A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing · Paula M. Fracasso · 2007 · 150 citations · Cited by this paper

Source: OpenAlex (CC0)